title: Clinical Significance of Vascular Endothelial Growth Factor Expression and Microvessel Density in Invasive Cervical Cancer.
abstract: To determine whether vascular endothelial growth factor (VEGF) expression and microvessel density are predictive of prognosis in cases of invasive cervical cancer, correlations among VEGF expression, microvessel density, and clinicopathological parameters were identified. VEGF expression was evaluated in 50 cervical cancer samples by immunohistochemical staining. Microvessel density was assessed by immunostaining for CD31-positive endothelial cells in the most vascularized areas of tumors. VEGF expression and microvessel density were significantly higher in adenocarcinomas than in squamous cell carcinomas. However, in cases of adenocarcinoma, no significant correlations were found among VEGF expression, microvessel density, and clinicopathological parameters. In contrast, for squamous cell carcinomas, microvessel density was significantly higher in cases at an advanced stage and in those with several other poor prognostic factors. The finding that cervical adenocarcinomas exhibited greater VEGF expression and microvessel density than squamous cell carcinomas may explain the poorer prognosis of adenocarcinoma compared with squamous cell carcinoma. Moreover, microvessel density in squamous cell carcinomas was significantly correlated with poor prognostic factors. Therefore, there is possibility that bevacizumab, a humanized monoclonal antibody against VEGF-A, may be useful in the initial treatment targeting angiogenesis for early-stage cervical cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Institute of Health Biosciences, the University of Tokushima Graduate School.
authors.forename: Yasuyo
authors.initials: Y
authors.lastname: Saijo
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Furumoto
authors.forename: Kanako
authors.initials: K
authors.lastname: Yoshida
authors.forename: Masato
authors.initials: M
authors.lastname: Nishimura
authors.forename: Minoru
authors.initials: M
authors.lastname: Irahara
mesh_terms: D000230:Adenocarcinoma; D000328:Adult; D000368:Aged; D000068258:Bevacizumab / Q000627:therapeutic use; D005260:Female; D006801:Humans; D055806:Microvessels / Q000033:anatomy & histology*; D008875:Middle Aged; D002583:Uterine Cervical Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis*
chemical_list: C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab